FAQ
Health Technology Assessment

How are pharmacoeconomic evaluations carried out? Are there any local reference or guideline?

刊登日期:2019-04-15  |  點閱次數 : 1344 次 

The purpose of pharmacoeconomics is to assess whether health technology is value for money. The most commonly used method is the cost-effectiveness analysis (CEA). The CEA tool can be used in the pharmacoeconomic evaluations for new health technologies National Health Insurance listing. However, considering the differences between Taiwan and other countries in demographic characteristics, payment environment, and clinical practice, the results of CEA conducted by other countries cannot be used to infer the situation in Taiwan. Therefore, even if other countries have evaluation studies on similar topics, policy makers still need to have local CEA results with Taiwan's conditions as a reference for decision-making. In order to promote the comparability of the CEA results of different health technologies in Taiwan, and to establish an empirically-based policy-making environment, the CDE has established CEA guidelines based on relevant domestic and international guidelines and Taiwan's conditions. In addition to quality assessment items used worldwide, the tool also contains an aspect assessing the study's representativeness of the local situation. In 2012, after pre-test on actual studies, discussion and revision by experts, call for public opinions and consultation of international experts, the abovementioned quality assessment report was discussed at the 18th Meeting of the 9th Term Drug Benefit Committee held on Sep 6, 2012, and subsequently announced in the meeting minutes. If pharmaceutics or research institutes are keen to carry out local pharmacoeconomic evaluations, it is recommended to refer to the methodology guidelines in the following link http://nihta.cde.org.tw/Service/rule_more?id=8.


上一筆 If the assessment reports from the UK, Canada and Australia are used as reference